Li, Yiwen <br/><br/>
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.  [electronic resource] 

 -  Journal of cardiac failure  Mar 2007 
 - 155-62 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-8414 
<br/><br/><label>Standard No.: </label>10.1016/j.cardfail.2006.11.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Animals<br/>Antihypertensive Agents--therapeutic use<br/>Blood Urea Nitrogen<br/>Blotting, Western<br/>Creatinine--blood<br/>DNA--genetics<br/>Disease Models, Animal<br/>Heart Failure--drug therapy<br/>Immunohistochemistry<br/>Kidney Failure, Chronic--complications<br/>Male<br/>Matrix Metalloproteinase 2--biosynthesis<br/>Matrix Metalloproteinase 9--biosynthesis<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Myocardium--metabolism<br/>Nephrectomy--adverse effects<br/>Oxidative Stress--genetics<br/>Receptor, Angiotensin, Type 1--blood<br/>Signal Transduction--physiology<br/>Tetrazoles--therapeutic use<br/>Tissue Inhibitor of Metalloproteinase-1--genetics<br/>Transforming Growth Factor beta1--biosynthesis<br/>Treatment Outcome<br/>Up-Regulation--drug effects<br/>Valine--analogs & derivatives<br/>Valsartan<br/>Ventricular Function, Left--drug effects